ReFaC hires Dr Virginia Gretton as technical officer

Has experience with all aspects of REACH registration

Dr Virginia Gretton has joined ReFaC, the REACH Facilitiation Company based in Crewe, Cheshire, UK, as technical officer.

Gretton was formerly regulatory manager at Harlan Laboratories, Derbyshire, where she was involved with all aspects of REACH registration and compliance. This covered data gap analysis, testing plans, exposure scenarios, risk assessment, classification and labelling, downstream user interaction, Safety Data Sheet preparation, as well as post-registration support.

In addition, Dr Gretton has held posts in academia and managed clinical research projects. She holds a DPhil in chemistry from the University of York, a BSc in combined science, and a post-graduate certificate in REACH management.

Peter Newport, ReFaC’s company secretary, said: ‘Virginia brings a wealth of practical regulatory experience, skills and technical knowledge to her new role, which will be invaluable in helping and advising clients on all aspects of REACH compliance.’

You may also like

Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Manufacturing

New thermal inkjet printer expands AM Labels’ coding portfolio

M2 system delivers high resolution variable data printing at production-line speeds
Regulatory

Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes

Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Regulatory

Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Subscribe now